Active Biotech focus on pharmaceutical development
Completed divestment of SBL Vaccin - capital gain for the Group of SEK 190 million (Parent Company, SEK 150). Cash injection of just over half a billion SEK
Phase I successes for SAIK-MS and TTS cancer projects
New patent applications for TTS and immunomodulatory substances
The operating loss -SEK 185.4 million (-SEK 125.6 m), prev. year adjusted to new accounting principles was -SEK 158.5 million
